Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has enrolled the first subjects in a phase I clinical study designed to assess the safety, tolerability and pharmacokinetics of Theravance's investigational, inhaled bronchodilator, GSK656398, for the treatment of chronic obstructive pulmonary disease.
Subscribe to our email newsletter
GSK656398 is an inhaled, long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory disease such as chronic obstructive pulmonary disease (COPD) and asthma. The LAMA program is one of three respiratory programs under joint development by GSK and Theravance.
“The goal for our program is to develop an effective once-a-day inhaled medicine that is better tolerated than the market leading medicines,” said Dr Michael Kitt, senior vice president of Development at Theravance. “In addition, at higher doses, a more lung-selective LAMA might offer improved efficacy with comparable or improved tolerability.”